Approval · Notice of Compliance 26043 · 2021
CELLCEPT: Notice of Compliance 26043
Issued June 10, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26043
- Date
- June 10, 2021
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph with regard to potential risk of increased COVID-19 severity. To migrate the Product Monograph to the 2020 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CELLCEPT | Not yet assigned | — |
| CELLCEPT I.V. | Not yet assigned | — |
Medicinal ingredients
- MYCOPHENOLATE MOFETIL 500 MG per TAB
- MYCOPHENOLATE MOFETIL 250 MG per TAB
- MYCOPHENOLATE MOFETIL 200 MG per TAB
- MYCOPHENOLATE MOFETIL 500 MG per VIAL